Fig. 6
EBY100-L2 (AOE1) immunization reduced β-amyloid peptide (Aβ) levels in the brains of Alzheimer’s disease (AD) mice. After the behavior test, the mouse brain homogenate was prepared by using radioimmunoprecipitation assay buffer (soluble fraction) and guanidinium chloride buffer (insoluble fraction), respectively. Soluble (a, b) and insoluble (c, d) Aβ40 (a, c) and Aβ42 (b, d) were determined using an Aβ enzyme-linked immunosorbent assay kit (a–d) (compared with AD control, *p < 0.05, **p < 0.01). e The Aβ oligomer levels in the brain extracts of mice immunized with or without AOE1 were detected by Western blot analysis, and the band density was quantified using IpWin5 software (f) (compared with AD control, *p < 0.05). GAPDH Glyceraldehyde 3-phosphate dehydrogenase, WT Wild type, IOD Integrated optical density